Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Redhill

Six-way title tilts and angry Bulls: non-league stories you may have missed

Astonishing final-game deciders, postponed playoffs and the unluckiest team in the country with 100 points

The Guardian - UK

Morrisons introduces gates which need proof of payment before shoppers can leave

Sainsbury's was recently called out for introducing the measure in several of its stores across the UK including Balham in south London, Redhill in Surrey, Colne in Lancashire, and Winnersh in Berkshire

Daily Mirror

Sainsbury's shoppers furious as more stores force customers to scan receipts to leave

People have reported seeing the security barriers in Sainsbury's stores in Balham south London, Redhill in Surrey, Colne in Lancashire, and Winnersh in Berkshire.

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

REV’IT! Presents The Redhill Retro-Style Leather Gloves

Dutch gear and equipment maker REV'IT! has launched the new Redhill retro-inspired leather gloves for light-duty rides in and around the city.

RideApart

The teacher who started his own school but won't be teaching the new curriculum

Former state school teacher Alun Millington went to a comprehensive and never set foot in a fee paying school until 2014 - now he runs one

Wales Online

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants

RedHill Biopharma Ltd's (NASDAQ:RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability. The Company says that based on the new and previously announced data, opaganib's dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

RedHill Biopharma Ltd (NASDAQ:RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million. Redhill is eligible for up to $5.6 million…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National League South

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.